This 1995 foundational review aggregates clinical and laboratory data to evaluate growth kinetics of various human solid tumors, including breast, lung, colorectal cancers, melanomas, and skeletal sarcomas. It analyzes tumor growth using both gross measurements (e.g., imaging, palpation) and cytokinetic parameters such as tritiated thymidine and bromodeoxyuridine labeling, S-phase fractions,
This 2022 review evaluates itraconazole, a triazole antifungal, as a repurposed anticancer agent. Itraconazole demonstrates anti-tumor activity by inhibiting angiogenesis and multiple oncogenic signaling pathways, notably the Hedgehog pathway. Preclinical studies show its efficacy in various solid and hematological malignancies. Clinical trials have reported benefits in prostate, lung, and basal
This 2004 Phase I clinical trial investigated the safety, pharmacokinetics, and preliminary efficacy of intravenous aviscumine (rViscumin), a recombinant mistletoe lectin, in 41 patients with advanced solid tumors refractory to standard therapies. Doses ranged from 10 to 6400 ng/kg, administered twice weekly. Dose-limiting toxicities included fatigue and reversible grade 3
The 2009 RECIST 1.1 guideline updates the original RECIST criteria to improve the consistency and accuracy of tumor response assessment in clinical trials. Key revisions include reducing the number of target lesions from 10 to a maximum of 5 (no more than 2 per organ), establishing a minimum lymph node
This 2019 study presents a novel statistical methodology to estimate tumor doubling times (TDTs) from published progression-free survival (PFS) plots, facilitating better understanding of tumor growth dynamics in solid malignancies. Researchers extracted PFS curves from clinical trials encompassing twelve cancer types, including pancreatic, melanoma, hepatocellular carcinoma, renal cell carcinoma, triple-negative
This Phase I clinical trial (NCT03051477) evaluates the safety, toxicity, and maximum tolerated dose (MTD) of Helixor® M (mistletoe extract) in 21 patients with advanced solid tumors who have not responded well to first-line therapies. The study consists of a dose escalation phase to assess safety and an expansion phase
